Market Research Report
Global Parenteral Nutrition Market -2019-2026
|Published by||DataM Intelligence||Product code||834571|
|Published||Content info||130-180 Pages
Delivery time: 1-2 business days
|Global Parenteral Nutrition Market -2019-2026|
|Published: May 1, 2019||Content info: 130-180 Pages||
The global parenteral nutrition market was worth the US $XX billion in 2018 and is expected to reach US $XX billion by 2026, at a CAGR of XX% during the forecast period.
Parenteral nutrition is a method of getting nutrition into the body through the veins, which include amino acids, carbohydrate, fat, minerals and electrolytes, vitamins, trace elements, and others for patients who cannot eat or absorb enough food through tube feeding formula or by mouth to maintain proper nutrition status. It is delivered either peripherally or centrally, through the superior vena cava, this helps in crossing the first-pass effect.
Increasing occurrence of chronic conditions, such as cancer, influencing the global parenteral nutrition market positively. The benefit of parenteral nutrition in chronic diseases helps in the provision of vital nutrients that help in maintaining the hydration level, strength, and energy to the patients. According to the International Agency for Research on Cancer (IARC), in 2018 there were 17.0 million new cancer cases worldwide, by 2040, it is expected to reach 27.5 million new cancer cases due to the growth and aging of the population. Thus, the increase in cancer cases is expected to drive the global parenteral nutrition market.
The rise in pediatric disorders will create mineral and vitamin deficiencies amongst children that will fuel the demand for parenteral nutrition products, thereby increasing the market growth. Additionally, extensive research and development activities by key players to develop new parenteral nutrition products and rising approvals to new parenteral nutrition components drive the market. In October 2018, Baxter in collaboration with the American Society for Parenteral and Enteral Nutrition (ASPEN) launched 'smartPN' tool to reduce clinical malnutrition.
Based on type the global Parenteral Nutrition market is broadly segmented as an amino acid, fats, minerals & vitamins, parenteral lipid emulsions, trace elements, and others. Among all, amino acids accounted for major market share in 2018, and is projected to grow at a high CAGR over the forecast period (2019-2026). It is due to increasing cases of renal insufficiency, hepatic insufficiency and protein-catabolic critical illness will globally boost the demand for amino acid-based parenteral nutrition products. Additionally, deficiency of energy and dietary proteins are customary in critically-ill hospitalized patients that ultimately lead to protein-energy malnutrition. Over the forecast period, parenteral lipid emulsion is expected to grow at a significant rate. Lipid emulsions are prescribed for pediatric patients as they are a non-carbohydrate source of energy. These lipid emulsions are a rich source of essential fatty acids. Also useful in maintaining overall nitrogen balance in parenteral nutrition solutions.
The global Parenteral Nutrition market is segmented into North America, Europe, Asia Pacific, South America, and Middle East & Africa. North America region accounted for major market share in 2018 and is projected to grow at a significant rate during the forecast period (2019-2026). The region will witness positive growth owing to rise in awareness about parenteral nutrition, increasing incidence of chronic diseases coupled with rising healthcare expenses, the existence of advanced healthcare facilities, as well as favorable reimbursement policies. Asia Pacific is projected to grow at a significant pace over the forecast period, owing to rapidly increasing population prone to malnutrition, rise in awareness among people and modernizing of healthcare infrastructure in developing nations such as China and India in this region.
Significant players of the global parenteral nutrition market are Sichuan Kelun Pharmaceutical Co., Ltd., Allergan plc (Actavis plc), Fresenius Kabi AG, Grifols S.A., Baxter International, Inc., Claris Lifesciences Limited, B. Braun Melsungen AG, Pfizer, Inc., and others. The product launches, collaboration, and product agreements, and other key developments are the dominating strategies adopted by the market players to enhance their product portfolio in the parenteral nutrition market. For instance, in October 2018, Fresenius Kabi Announced U.S. Availability of Omegaven® (fish oil triglycerides) Injectable Emulsion.
In September 2018, Fresenius Kabi announced the winner of the first EUR 100,000* Parenteral Nutrition Research Grant in Latin America at the FELANPE congress in Guadalajara, Mexico.
In January 2018, B. Braun's Parenteral Nutrition launched 360 (PN360) program - a comprehensive approach designed to improve neonatal, pediatric and adult patient outcomes.
In February 2016, Telstar and B.Braun double booth equipment for parenteral nutrition was installed in parenteral nutrition facilities at Alcobendas, Spain
In September 2014, B.Braun Medical, Inc. announced it had received FDA approval of Nutrilipid 20%, an IV fat emulsion product for parenteral nutrition therapy in adult and pediatric patients.